Quarterly report pursuant to Section 13 or 15(d)

Nature of Operations, Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements - Additional Information (Detail)

v2.4.0.8
Nature of Operations, Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements - Additional Information (Detail) (USD $)
 3 Months Ended 9 Months Ended 0 Months Ended 0 Months Ended 0 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Segment
Sep. 30, 2013
Aug. 31, 2014
Dec. 31, 2013
Jun. 30, 2013
Dec. 31, 2012
Oct. 31, 2009
Apr. 11, 2014
Corbus Pharmaceuticals Inc [Member]
Sep. 30, 2014
Corbus Pharmaceuticals Inc [Member]
Apr. 11, 2014
Corbus Pharmaceuticals Inc [Member]
Apr. 11, 2014
Series A Convertible Preferred Stock [Member]
Corbus Pharmaceuticals Inc [Member]
Apr. 11, 2014
Minimum [Member]
Corbus Pharmaceuticals Inc [Member]
Apr. 11, 2014
Minimum [Member]
Corbus Pharmaceuticals Inc [Member]
Apr. 11, 2014
Maximum [Member]
Corbus Pharmaceuticals Inc [Member]
Apr. 11, 2014
Maximum [Member]
Corbus Pharmaceuticals Inc [Member]
Nature Of Operations And Summary Of Significant Accounting Policies [Line Items]                                  
Conversion of Stock, Shares issued                   9,000,000              
Number of shares converted to common stock                   5,964,649              
Number of common stock called by warrants         162,539 301,778 301,778   27,839     377,839 917,612        
Common stock warrants, exercise price                             $ 0.60   $ 0.66
Number of options to purchase shares of common stock                   905,334              
Options exercise price                           $ 0.11   $ 0.17  
Exchange ratio of shares                     1.5089            
Common Stock Shares , outstanding 25,801,948   25,801,948     6,964,788           6,000,000          
Private placement of equity, net proceeds     $ 8,454,000                            
Cash and cash equivalents 7,536,354 331,272 7,536,354 331,272   303,020   542,483                  
Restricted cash 13,725   13,725                            
Reduction in research and development expense 0 60,000 49,000 175,000                          
Operating segments     1                            
Valuation allowance     100.00%                            
Uncertain tax position 0   0     0                      
Impairment charges     $ 0 $ 0